Safety, pharmacodynamic, and pharmacokinetic characterization of vericiguat: results from six phase I studies in healthy subjects

ConclusionIn general, vericiguat was well tolerated. These results supported further clinical evaluation of vericiguat QD in patients with heart failure.Registry numbersEudraCT: 2011-001627-21; EudraCT: 2012-000953-30

Source: European Journal of Clinical Pharmacology - October 30, 2020 Category: Drugs & Pharmacology Source Type: research